Since the approval of dextromethorphan-bupropion in 2022, there has been an increasing trend in AEs, which peaked in 2024.
← all excerpts
Dextromethorphan-bupropion-associated pharmacovigilance signals based on the FAERS database: An observational study.
1
—
—